U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H33ClN2O5S
Molecular Weight 424.9847
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLINDAMYCIN

SMILES

CCC[C@]1([H])C[C@@]([H])(C(=N[C@]([H])([C@]([H])(C)Cl)[C@]2([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(O2)SC)O)O)O)O)N(C)C1

InChI

InChIKey=KDLRVYVGXIQJDK-AWPVFWJPSA-N
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H33ClN2O5S
Molecular Weight 424.9847
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Curator's Comment:: with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4492800000
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4492800000
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4492800000
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4492800000
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4492800000
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4492800000
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4492800000
Curative
CLEOCIN T

Approved Use

Clindamycin Phosphate is indicated in the treatment of acne vulgaris.

Launch Date

331862400000
Curative
CLEOCIN PHOSPHATE

Approved Use

Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus.

Launch Date

86745600000
Curative
CLEOCIN PHOSPHATE

Approved Use

Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes.

Launch Date

86745600000
Curative
CLEOCIN PHOSPHATE

Approved Use

Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Launch Date

86745600000
Curative
CLEOCIN PHOSPHATE

Approved Use

Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.

Launch Date

86745600000
Curative
CLEOCIN PHOSPHATE

Approved Use

Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes.

Launch Date

86745600000
Curative
CLEOCIN PHOSPHATE

Approved Use

Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.

Launch Date

86745600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.92 ng/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.2 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.54 ng × h/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources:
unhealthy, 16 - 51
Health Status: unhealthy
Age Group: 16 - 51
Sex: F
Sources:
Disc. AE: Vaginal pain or burning...
AEs leading to
discontinuation/dose reduction:
Vaginal pain or burning (1.2%)
Sources:
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources:
unhealthy
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Reaction skin (severe)
Toxic epidermal necrolysis (grade 3-5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vaginal pain or burning 1.2%
Disc. AE
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources:
unhealthy, 16 - 51
Health Status: unhealthy
Age Group: 16 - 51
Sex: F
Sources:
Anaphylactic shock Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Diarrhea, Clostridium difficile Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Hypersensitivity reaction severe
Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Diarrhea, Clostridium difficile Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources:
unhealthy
Toxic epidermal necrolysis grade 3-5
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources:
unhealthy
Reaction skin severe
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources:
unhealthy
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5
minor
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5
not determined
not determined
not determined
not determined
not determined
not determined
not determined
not determined
PubMed

PubMed

TitleDatePubMed
A simple, efficient and inexpensive program for preventing prematurity.
2001
Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis.
2001
Superantigen antagonist peptides.
2001
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia.
2001 Apr
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.
2001 Apr
Chronic granulomatous disease: a case report.
2001 Apr
Thoracic spondylitis mimicking idiopathic scoliosis: a case report.
2001 Apr
[The latest trend of PRSP infection].
2001 Apr
Severe babesiosis in Long Island: review of 34 cases and their complications.
2001 Apr 15
Clindamycin suspension and endocarditis prophylaxis.
2001 Apr 28
Laparoscopic management of adnexal masses.
2001 Apr-Jun
Successful treatment regime for folliculitis decalvans despite uncertainty of all aetiological factors.
2001 Feb
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.
2001 Feb
Clostridium difficile--Associated diarrhea: A review.
2001 Feb 26
[Guidelines for antibiotic prophylaxis of bacterial endocarditis in patients undergoing dental therapy].
2001 Jan
Folliculitis decalvans.
2001 Jan
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.
2001 Jan
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product.
2001 Jan-Feb
Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents.
2001 Jul
A rare case of primary group A streptococcal peritonitis.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads.
2001 Jul
Cutaneous botryomycosis of the cervicofacial region.
2001 Jul
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.
2001 Jun
The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.
2001 Jun
Eikenella corrodens: an unusual cause of severe parapneumonic infection and empyema in immunocompetent patients.
2001 Jun
[Chronic osteomyelitis of the ilium after autologous bone harvesting in Albers-Schonberg osteopetrosis. A case report].
2001 Jun
Bilateral peritonsillar abscess: case report and presentation of its clinical appearance.
2001 Jun
Transfusion-transmitted babesiosis in Ontario: first reported case in Canada.
2001 Jun 12
Infection of hamsters with epidemiologically important strains of Clostridium difficile.
2001 Jun 15
Antibiotic susceptibility of Clostridium difficile isolates from adult patients at two Jamaican hospitals. Clinical and epidemiological implications.
2001 Mar
A 2-step non-surgical procedure and systemic antibiotics in the treatment of rapidly progressive periodontitis.
2001 Mar
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
2001 Mar
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.
2001 Mar
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.
2001 Mar
Antibiotic-resistant bacteria in pediatric chronic sinusitis.
2001 Mar
Detection and characterization of a bacteriocin, garviecin L1-5, produced by Lactococcus garvieae isolated from raw cow's milk.
2001 Mar
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.
2001 Mar
Tufted hair folliculitis after scalp injury.
2001 Mar
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
2001 Mar
Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan.
2001 May
Effect of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in Babesia rodhaini-infected mice.
2001 May
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women?
2001 May
Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures.
2001 May
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.
2001 May
When to suspect and how to monitor babesiosis.
2001 May 15
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
2001 May-Jun
Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis.
2001 May-Jun
Isolation and antimicrobial susceptibility testing of fecal strains of the archaeon Methanobrevibacter smithii.
2001 May-Jun
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.
2001 Spring
Patents

Sample Use Guides

150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:51:27 UTC 2021
Edited
by admin
on Sat Jun 26 09:51:27 UTC 2021
Record UNII
3U02EL437C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLINDAMYCIN
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
CLINDAMYCIN PHOSPHATE IMPURITY E [EP]
Common Name English
U-21,251
Code English
CLINDAMYCIN [INN]
Common Name English
U-21251
Code English
CLINDAMYCIN [WHO-DD]
Common Name English
CLINDAMYCIN [MART.]
Common Name English
CLINDAMYCIN [USAN]
Common Name English
CLINDAMYCIN [GREEN BOOK]
Common Name English
METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE
Common Name English
7(S)-CHLORO-7-DEOXYLINCOMYCIN
Common Name English
CLINDAMYCIN [VANDF]
Common Name English
CLINDAMYCIN [HSDB]
Common Name English
L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, (2S-TRANS)-
Common Name English
CLINDAMYCIN [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QD10AF01
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
CFR 21 CFR 520.447
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-ATC J01FF01
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-VATC QJ01FF01
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
NDF-RT N0000175442
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-ATC G01AA10
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
CFR 21 CFR 520.446
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-ATC D10AF51
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
LIVERTOX 217
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
NDF-RT N0000175442
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
NDF-RT N0000175443
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-VATC QG01AA10
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-ATC D10AF01
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
FDA ORPHAN DRUG 26988
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
NDF-RT N0000009982
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
NCI_THESAURUS C82922
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
FDA ORPHAN DRUG 27088
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
WHO-VATC QD10AF51
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
Code System Code Type Description
LACTMED
Clindamycin
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
INN
2550
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
WIKIPEDIA
CLINDAMYCIN
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
MERCK INDEX
M3624
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY Merck Index
FDA UNII
3U02EL437C
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
EPA CompTox
18323-44-9
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
DRUG CENTRAL
678
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
CAS
18323-44-9
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
NCI_THESAURUS
C377
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
EVMPD
SUB06665MIG
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
ECHA (EC/EINECS)
242-209-1
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
MESH
D002981
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL1753
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
PUBCHEM
446598
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
RXCUI
2582
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY RxNorm
HSDB
3037
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
DRUG BANK
DB01190
Created by admin on Sat Jun 26 09:51:29 UTC 2021 , Edited by admin on Sat Jun 26 09:51:29 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
PARENT -> METABOLITE
IN VITRO
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ROUTE OF ADMINSTRATION: IM

MIC BIOLOGICAL PATHOGEN: ANAEROBIC BACTERIA

SUSCEPTIBILITY: INTERMEDIATE

ORAL BIOAVAILABILITY PHARMACOKINETIC
Biological Half-life BIOLOGICAL POPULATION: ELDERLY

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: ANAEROBIC BACTERIA

MIC BIOLOGICAL PATHOGEN: STAPHYLOCOCCUS spp.

SUSCEPTIBILITY: SUSCEPTIBLE

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL PATHOGEN: STAPHYLOCOCCUS spp.

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL PATHOGEN: STAPHYLOCOCCUS spp.

SUSCEPTIBILITY: INTERMEDIATE

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS

Biological Half-life PHARMACOKINETIC POPULATION: PREMATURE NEONATES

MIC BIOLOGICAL PATHOGEN: S. PNEUMONIAE AND OTHER STREPTOCOCCUS spp.

SUSCEPTIBILITY: INTERMEDIATE

Biological Half-life PHARMACOKINETIC POPULATION: FULL-TERM NEONATES

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: S. PNEUMONIAE AND OTHER STREPTOCOCCUS spp.

Biological Half-life PHARMACOKINETIC POPULATION: INFANTS 1 MONTH TO 1 YEAR

MIC BIOLOGICAL PATHOGEN: S. PNEUMONIAE AND OTHER STREPTOCOCCUS spp.

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: ANAEROBIC BACTERIA